A Phase II Trial of Dasatinib in Patients With Unresectable Locally Advanced or Stage IV Mucosal, Acral and Vulvovaginal Melanomas.
Phase of Trial: Phase II
Latest Information Update: 18 Dec 2017
At a glance
- Drugs Dasatinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 23 Mar 2017 Primary endpoint has not been met. (Objective tumor response rate) as per results published in the Cancer.
- 23 Mar 2017 Status changed to discontinued as per results published in the Cancer